Sutro Biopharma Regains Nasdaq Listing Compliance

An update from Sutro Biopharma ( (STRO) ) is now available.

On December 17, 2025, Sutro Biopharma announced that it had regained compliance with Nasdaq Listing Rule 5450(a)(1), closing a listing matter that began on June 20, 2025, when its stock price fell below $1.00 per share for 30 consecutive business days. As of December 16, 2025, the company’s stock maintained a bid price of at least $1.00 per share for 10 consecutive business days, meeting the key requirement for continued listing on the Nasdaq Global Market, alongside other applicable criteria. The resolution of this issue marks a positive development for the company’s operations and market standing, ensuring its continued access to the critical resources offered by Nasdaq.

The most recent analyst rating on (STRO) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.

Spark’s Take on STRO Stock

According to Spark, TipRanks’ AI Analyst, STRO is a Neutral.

Sutro Biopharma’s overall stock score is primarily impacted by its financial instability and negative valuation metrics. The technical analysis indicates a lack of strong momentum, while the corporate restructuring presents both potential cost savings and operational risks. The absence of earnings call data limits insights into management’s strategic direction.

To see Spark’s full report on STRO stock, click here.

More about Sutro Biopharma

Sutro Biopharma, Inc. operates within the biopharmaceutical industry, specializing in the development of oncology-focused therapeutics. The company is known for its proprietary cell-free protein synthesis platform, which aids in designing complex biologic medicines to advance cancer treatment options.

Average Trading Volume: 110,059

Technical Sentiment Signal: Sell

Current Market Cap: $83.58M

See more insights into STRO stock on TipRanks’ Stock Analysis page.